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EDITORIAL  COMMENT
Improved Outcome of Acute Esophageal
Variceal Bleeding
Liver cirrhosis has long been considered a chronic,
progressive, and irreversible disease with the focus of
treatment mainly on its complications. There have
been significant advances in the treatment of esophageal
variceal bleeding, as reflected by the marked reduction
of rebleeding from 47% to 13% and bleeding-related
death from 50% to 20%.1,2 This achievement has been
attributed to a better understanding of the pathogenesis
of portal hypertension and improved standards of
medical care. The introduction of endoscopic variceal
ligation, a technique that is at least as effective as
sclerotherapy but associated with fewer side effects, as
well as the near global use of vasoactive agents, has
contributed to this improvement in survival. Moreover,
the prophylactic use of antibiotics has resulted in the
reduction of infection to 32% and mortality to 9%.3 In
a recently reported trial, antibiotic prophylaxis reduced
early variceal rebleeding and rebleeding severity.
Although all of these measures have improved
outcomes,4 incidences of failure to control acute
bleeding and early rebleeding are still high, at around
20–30%; thus, the continued improvement of outcome
in patients with acute variceal bleeding is required.
Emergency Endoscopic Treatment or
Vasoactive Agents?
The global use of vasoactive agents for acute variceal
bleeding is known to be effective in controlling
approximately 70–80% of acute variceal bleeding
episodes. A recent meta-analysis by D’Amico et al5
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has suggested reserving endoscopic therapy for
use only after failure of pharmacologic treatment.
Another randomized trial showed that if hemostasis is
achieved by pharmacologic treatment, continuous
somatostatin infusion is as effective as sclerotherapy
but with fewer side effects,6 which reinforces the
conclusion of D’Amico at al.5 Indeed, endoscopic
treatments are equally effective in controlling acute
variceal bleeding in all of the studies that compared
sclerotherapy versus vasoactive agents.5 Endoscopic
variceal ligation (EVL) has replaced sclerotherapy as
the optimal endoscopic method to treat acute
esophageal variceal bleeding, primarily because of its
lower complication rate and lower rebleeding rate.
Therefore, the hemostatic effects of vasoactive agents
versus EVL on acute variceal bleeding should be
reassessed before a conclusion such as “endoscopic
therapy might be reserved for failure of pharmacological
treatment”5 can be drawn.
Consensus for the Treatment of Acute
Esophageal Variceal Bleeding
Evidence for the beneficial effect of early administration
of vasoactive agents to patients with suspected acute
esophageal variceal bleeding have been gathered from
many studies to substantiate the Baveno III consensus
that “In suspected variceal bleeding, vasoactive drugs
should start as soon as possible, before diagnostic
endoscopy. Endoscopic therapy is recommended even
when no active bleeding is found at diagnostic
endoscopy.”7 Therefore, the consensus of how to treat
acute esophageal variceal bleeding changed and a
study designed to compare EVL versus vasoactive
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agents in the treatment of acute esophageal variceal
bleeding has become impossible. From now on, a
delay in giving vasoactive agents to patients with
suspected esophageal bleeding before endoscopic
diagnosis or treatment is deemed unethical.
Emergency Endoscopic Variceal Ligation
or Vasoactive Agents — Which Is Better?
This difficult question is answered by Chen et al8 in this
issue of the Journal of the Chinese Medical Association.
This unique study was conducted just before the
Baveno III consensus was reached in 2001. The study
randomized patients with acute esophageal variceal
bleeding to receive emergency EVL or somatostatin
(250 +g bolus followed by 250 +g/hour for 48
hours). Finding a higher treatment failure rate (3/62
vs 20/63) and more transfusion requirement (4.7 (
3.2 vs 6.9 ( 7.3 units) in the somatostatin group,
regardless of active or nonactive bleeding, the authors
suggested that early EVL for patients with acute
esophageal variceal bleeding is encouraged if
endoscopists experienced in EVL are available. While
the study was conducted by a renowned collaborative
team and drew some important conclusions from solid
results, it does raise several concerns.
Myth or Reality
First, rebleeding was ascertained when a nasogastric
tube (NG) showed blood; however, an NG was only
inserted to monitor the patients receiving somatostatin,
but not in patients undergoing EVL, and this may
underestimate the treatment failure rate of the latter
group. Second, a time lag in the definitive treatment
by either EVL or vasoactives may underestimate the
success rate of controlling bleeding because vasoactive
agents are known to be more effective when given
earlier, if possible at the scene of bleeding, and are less
effective if patients already have hypotension or shock.9
Third, a double dose of somatostatin infusion (500
+g/hour) may be more effective than the standard
250 +g/hour dose in patients with active bleeding at
endoscopy.10 Therefore, it is still uncertain whether
the failure rate of double-dose somatostatin is higher
than that of EVL. Questions regarding the real efficacy
of vasoactive agents versus EVL in controlling acute
esophageal variceal bleeding remain unsettled and
may be forever a myth. In reality, suspected patients
will already have received vasoactive agents, which can
be easily administered by a junior resident, before
endoscopy. As soon as possible, endoscopy is then
performed by a senior resident. If acute esophageal
variceal bleeding is found, ligation of the varices would
seem proper if endoscopists experienced in EVL are
available. But what is the next step? A recent meta-
analysis has shown that combination of endoscopic
plus pharmacologic treatment is more effective than
endoscopic treatment alone in controlling acute
variceal bleeding, but has no effect on mortality.11
Theoretically, it is understandable because control of
acute esophageal variceal bleeding by endoscopic
treatment and vasoactive agents are mediated via
different mechanisms. Actually, the Baveno IV
consensus workshop recommends that “Endoscopic
treatments are best used in association with
pharmacological therapy, which preferably should be
started before endoscopy. Vasoactive drug therapy
(terlipressin, somatostatin, vapreotide or octreotide)
should be maintained in patients with esophageal
variceal bleeding for 2–5 days.”12
Solving the Unsolved
Despite the agreed treatment strategy, failure to control
acute bleeding and early rebleeding is still a challenge,
especially in patients with high risk of rebleeding, such
as active bleeding during endoscopy, severe hepatic
decompensation, and association of hepatocellular
carcinoma. Hemostasis is markedly impaired since
liver plays an important role in the production and
clearance of clotting and fibrinolytic factors. The role
of coagulopathy and thrombocytopenia in the outcome
of acute variceal bleeding, and their therapeutic effect
of correction or amelioration have not been well
evaluated. A recent multicenter European trial has
shown that the administration of recombinant activated
Factor VII, in addition to combined endoscopic plus
pharmacologic treatment, improves the results of
endoscopic plus pharmacologic treatment alone in
Child’s class B and C patients but not in Child’s
class A .13 However, more controlled trials are required
to assess its efficacy and cost-benefit.
Going Forward
Since variceal bleeding is a medical emergency
associated with significant morbidity and mortality,
the design and conduct of good clinical trials for the
treatment of this emergency have always been difficult.
However, it is our responsibility to continue improving
outcomes in patients with acute variceal bleeding.
Treatment of acute esophageal variceal bleeding
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